cytarabine has been researched along with 2-fluoro-araatp in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gandhi, V; Plunkett, W | 3 |
| Gandhi, V; Keating, M; Kemena, A; Plunkett, W; Shewach, DS | 1 |
| Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W | 1 |
| Gandhi, V; Keating, MJ; Plunkett, W; Robertson, LE | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
7 other study(ies) available for cytarabine and 2-fluoro-araatp
| Article | Year |
|---|---|
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cell Cycle; Cytarabine; Deoxycytidine Kinase; Drug Synergism; G1 Phase; G2 Phase; Humans; Intracellular Fluid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Metaphase; Nucleotides; S Phase; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1992 |
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytarabine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Time Factors; Vidarabine | 1992 |
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.
Topics: Arabinonucleosides; Arabinonucleotides; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Leukemia; Phosphorylation; Tumor Cells, Cultured; Vidarabine | 1990 |
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Humans; Leukemia; Phosphorylation; Tumor Cells, Cultured; Vidarabine | 1988 |
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 1987 |
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Drug Administration Schedule; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Time Factors; Vidarabine | 1997 |